Your browser version may not work well with NCBI's Web applications. More information here...
1: Mol Cancer Res. 2007 Oct;5(10):981-9.Click here to read Links

Histone deacetylase inhibitors: overview and perspectives.

Dokmanovic M, Clarke C, Marks PA.

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death.

PMID: 17951399 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Vorinostat (Zolinza® )

    Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medi...

  • Source: AHFS Consumer Medication Information